Search Videos and More
News
Dana-Farber and Gustave Roussy to Hold Third Transatlantic Exchange: Annual Scientific Conference Dedicated to Advancing Oncology Research and Practice
Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Third Transatlantic Exchange in Oncology Conference will address Liquid Biopsy as an Emerging Approach in Precision Cancer Medicine.
Document
Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.
News
Ultrasensitive Blood Test Detects ‘Pan-Cancer’ Biomarker
Diagnostic tools for timely, accurate and inexpensive early cancer detection that can assess risk or monitor response to treatment could help patients get the care they need faster and improve existing care strategies.
News
Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction
Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
News
New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines
In order to accurately assess the efficacy of novel therapies for brain tumors it is necessary to have reliable criteria to determine response or progression.
News
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer
A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
News
Cell Therapy That Repairs Cornea Damage with Patient’s Own Stem Cells Achieves Positive Phase I Trial Results
A team led by researchers from Dana-Farber Cancer Institute and Mass Eye and Ear, a member of Mass General Brigham, reports the results of a phase I trial of a revolutionary stem cell treatment called cultivated autologous limbal epithelial cell transplantation (CALEC), which was found to be safe and well-tolerated over the short term in four patients with significant chemical burns in one eye.
News
Errant Cell Division Can Lead to Changes in Gene Activity, Study Finds
There are several ways to ruin a tune: play the wrong notes, play them at the wrong time, or with the wrong emphasis.
News
Live Cell Imaging IDs Bad Actors in Cancer and Finds Possible Ways to Defeat Them
Most forms of chemotherapy are designed to kill cancer cells. But some cancer cells survive. Those that do can cause the cancer to relapse.
News
Origins of Glioma Brain Cancer Found to be in the Epigenome
While cancers often originate from mutations and other alterations of cells' DNA, researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas – incurable brain tumors – can arise due to changes in the epigenome, the collection of compounds that are deposited on DNA and alter gene activity without changing the sequence of DNA itself.
News
Obesity and High Weight Linked to Adverse Outcomes In Leukemia Treatment
As the United States faces a growing obesity epidemic, scientists are taking a closer look at how body weight can affect health outcomes.
News
Study Suggests Lymphoma Patients with Depression or Anxiety Experience Shorter Survival Times
Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber Cancer Institute researchers and published in The Lancet Hematology.